15353-j-veluchamy

158 | Chapter 6 21. Mathios D, Park C-K, Marcus WD, Alter S, Rhode PR, Jeng EK, et al. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. International journal of cancer Journal international du cancer (2016) 138 (1):187-94. doi: 10.1002/ijc.29686. PubMed PMID: PMC4696021. 22. Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, et al. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One (2014) 9 (6):e96705. Epub 2014/06/05. doi: 10.1371/journal.pone.0096705. PubMed PMID: 24896845; PubMed Central PMCID: PMCPMC4045574. 23. Kim PS, Kwilas AR, Xu W, Alter S, Jeng EK, Wong HC, et al. IL-15 superagonist/IL-15RalphaSushi-Fc fusion complex (IL-15SA/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget (2016) 7 (13):16130-45. Epub 2016/02/26. doi: 10.18632/ oncotarget.7470. PubMed PMID: 26910920; PubMed Central PMCID: PMCPMC4941302. 24. Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, et al. The IL-15-Based ALT-803 Complex Enhances FcgammaRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res (2016) 22 (3):596-608. Epub 2015/10/02. doi: 10.1158/1078-0432.ccr-15-1419. PubMed PMID: 26423796; PubMed Central PMCID: PMCPMC4738096. 25. Fehniger TA, Stuart RK, Cooley SA, Miller JS, Curtsinger J, Hillman TM, et al. Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission. Blood (2014) 124 (21):2320-. 26. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, et al. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin Cancer Res (2004) 10 (11):3699-707. Epub 2004/06/03. doi: 10.1158/1078-0432.ccr-03-0683. PubMed PMID: 15173076. 27. Frei GM, Persi N, Lador C, Peled A, Cohen YC, Nagler A, et al. Nicotinamide, a Form of Vitamin B<sub>3</sub>, Promotes Expansion of Natural Killer Cells That Display Increased In Vivo Survival and Cytotoxic Activity. Blood (2011) 118 (21):4035-. 28. Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, et al. Advantages and applications of CAR-expressing natural killer cells. Frontiers in pharmacology (2015) 6 :21. Epub 2015/03/03. doi: 10.3389/fphar.2015.00021. PubMed PMID: 25729364; PubMed Central PMCID: PMCPMC4325659. 29. Altvater B, Landmeier S, Pscherer S, Temme J, Schweer K, Kailayangiri S, et al. 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 15 (15):4857-66. Epub 2009/07/30. doi: 10.1158/1078-0432.ccr-08-2810. PubMed PMID: 19638467; PubMed Central PMCID: PMCPMC2771629. 30. Zhang G, Liu R, Zhu X, Wang L, Ma J, Han H, et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunol Cell Biol (2013) 91 (10):615-24. Epub 2013/10/09. doi: 10.1038/icb.2013.45. PubMed PMID: 24100387.